GlassScriptPhysician profile
Nancy Cardona
NPI 1902958739
$3,891.57
in general payments reported to CMS, 2019-2025
22 companies · $761 in 2025
The $761 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $982 · 2022: $458 · 2023: $705 · 2024: $985 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,351 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,351.02 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,812.44 | 2021-2025 | |
| Pfizer INC. | $551.88 | 2021-2025 | |
| Janssen Biotech, INC. | $326.49 | 2021-2024 | Stelara, Tremfya, Simponi Aria |
| Madrigal Pharmaceuticals | $283.14 | 2024-2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.05 | 2021-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $124.46 | 2021-2024 | Entyvio, Gattex |
| Genzyme Corporation | $84.45 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $61.89 | 2023-2024 | Dupixent |
| Celgene Corporation | $50.15 | 2022 | |
| Vivus LLC | $47.13 | 2021-2024 | Pancreaze |
| Mallinckrodt Hospital Products INC. | $47.09 | 2024 | Terlivaz |
| Intercept Pharmaceuticals, INC. | $39.29 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $36.27 | 2024 | Bylvay, Iqirvo |
| Evoke Pharma, INC. | $35.03 | 2021-2022 | |
| Exact Sciences Corporation | $32.29 | 2025 | The Cologuard Plus Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $24.80 | 2024 | Axonics |
| Mauna Kea Technologies, INC. | $24.68 | 2024 | |
| Amag Pharmaceuticals, INC. | $19.96 | 2021 | |
| Merck Sharp & Dohme LLC | $15.91 | 2023 | Dificid |
| Lilly USA, LLC | $14.45 | 2024 | Mounjaro |
| Aimmune Therapeutics, INC. | $14.43 | 2025 | Vowst |
| Braintree Laboratories, INC. | $13.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Cardona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.